Published in Antimicrob Agents Chemother on September 01, 1992
Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol (1993) 8.95
Proton-dependent multidrug efflux systems. Microbiol Rev (1996) 8.81
Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 6.65
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother (1994) 4.87
Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother (1999) 4.57
Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrob Agents Chemother (1994) 4.43
Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 3.98
Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agents Chemother (1996) 3.86
Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 3.78
Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother (2000) 3.22
A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2000) 2.91
In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother (1999) 2.90
Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 2.67
Influence of the MexAB-OprM multidrug efflux system on quorum sensing in Pseudomonas aeruginosa. J Bacteriol (1998) 2.61
Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol (2000) 2.41
Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med (2002) 2.40
Characterization of the MexC-MexD-OprJ multidrug efflux system in DeltamexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1998) 2.29
The outer membrane protein OprM of Pseudomonas aeruginosa is encoded by oprK of the mexA-mexB-oprK multidrug resistance operon. Antimicrob Agents Chemother (1995) 2.25
Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother (1999) 2.20
Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1996) 2.18
Contribution of outer membrane efflux protein OprM to antibiotic resistance in Pseudomonas aeruginosa independent of MexAB. Antimicrob Agents Chemother (1998) 2.14
Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 2.11
Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1997) 2.06
Role of the multidrug efflux systems of Pseudomonas aeruginosa in organic solvent tolerance. J Bacteriol (1998) 2.04
Influence of mutations in the mexR repressor gene on expression of the MexA-MexB-oprM multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol (2000) 1.98
Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother (2003) 1.97
Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1998) 1.96
Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol (1999) 1.96
Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother (2001) 1.96
Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1996) 1.94
Pseudomonas aeruginosa fur overlaps with a gene encoding a novel outer membrane lipoprotein, OmlA. J Bacteriol (1999) 1.89
MexR repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa: identification of MexR binding sites in the mexA-mexR intergenic region. J Bacteriol (2001) 1.86
In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity. Antimicrob Agents Chemother (1993) 1.85
OprK and OprM define two genetically distinct multidrug efflux systems in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.83
The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev (2015) 1.81
Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.81
Salt-resistant alpha-helical cationic antimicrobial peptides. Antimicrob Agents Chemother (1999) 1.78
Differential impact of MexB mutations on substrate selectivity of the MexAB-OprM multidrug efflux pump of Pseudomonas aeruginosa. J Bacteriol (2004) 1.54
Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.51
Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 1.46
Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules. J Bacteriol (2010) 1.35
Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product. J Bacteriol (2006) 1.29
Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.27
Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome. BMC Microbiol (2006) 1.26
Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Antimicrob Agents Chemother (2001) 1.26
MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa: involvement in chlorhexidine resistance and induction by membrane-damaging agents dependent upon the AlgU stress response sigma factor. Antimicrob Agents Chemother (2008) 1.17
In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother (1997) 1.17
Transient carbapenem resistance induced by salicylate in Pseudomonas aeruginosa associated with suppression of outer membrane protein D2 synthesis. Antimicrob Agents Chemother (1993) 1.16
nalD encodes a second repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa. J Bacteriol (2006) 1.16
Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob Agents Chemother (1995) 1.13
Assembly of the MexAB-OprM multidrug efflux system of Pseudomonas aeruginosa: identification and characterization of mutations in mexA compromising MexA multimerization and interaction with MexB. J Bacteriol (2004) 1.12
The mexR repressor of the mexAB-oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mutations compromising activity. J Bacteriol (2002) 1.11
Influence of OprM expression on multiple antibiotic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1997) 1.11
Mutational analysis of the OprM outer membrane component of the MexA-MexB-OprM multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol (2001) 1.07
FpvIR control of fpvA ferric pyoverdine receptor gene expression in Pseudomonas aeruginosa: demonstration of an interaction between FpvI and FpvR and identification of mutations in each compromising this interaction. J Bacteriol (2005) 1.06
Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the gram-negative pathogen Pseudomonas aeruginosa. Antimicrob Agents Chemother (2011) 0.96
Oxidative stress induction of the MexXY multidrug efflux genes and promotion of aminoglycoside resistance development in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2010) 0.95
Assembly of the MexAB-OprM multidrug pump of Pseudomonas aeruginosa: component interactions defined by the study of pump mutant suppressors. J Bacteriol (2007) 0.95
Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa. Front Microbiol (2015) 0.94
Protein modulator of multidrug efflux gene expression in Pseudomonas aeruginosa. J Bacteriol (2007) 0.93
Differential effects of mutations in tonB1 on intrinsic multidrug resistance and iron acquisition in Pseudomonas aeruginosa. J Bacteriol (2002) 0.93
Hypersusceptibility of the Pseudomonas aeruginosa nfxB mutant to beta-lactams due to reduced expression of the ampC beta-lactamase. Antimicrob Agents Chemother (2001) 0.92
Translational control of the antibiotic inducibility of the PA5471 gene required for mexXY multidrug efflux gene expression in Pseudomonas aeruginosa. J Bacteriol (2009) 0.92
Epidemiological analysis of sequential Pseudomonas aeruginosa isolates from chronic bronchiectasis patients without cystic fibrosis. J Clin Microbiol (1999) 0.92
Antibiotic inducibility of the mexXY multidrug efflux operon of Pseudomonas aeruginosa: involvement of the MexZ anti-repressor ArmZ. PLoS One (2013) 0.89
Bacterial resistance to fluoroquinolones: lessons to be learned. Infection (1994) 0.89
Mature Pseudomonas aeruginosa biofilms prevail compared to young biofilms in the presence of ceftazidime. Antimicrob Agents Chemother (2012) 0.89
Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2012) 0.88
Molecular Dynamics Computer Simulations of Multidrug RND Efflux Pumps. Comput Struct Biotechnol J (2013) 0.87
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 0.85
Mutational activation of the AmgRS two-component system in aminoglycoside-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (2013) 0.85
Reduced expression of the rplU-rpmA ribosomal protein operon in mexXY-expressing pan-aminoglycoside-resistant mutants of pseudomonas aeruginosa. Antimicrob Agents Chemother (2012) 0.85
Evaluation of the E test for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from patients with long-term bladder catheterization. J Clin Microbiol (1998) 0.84
In vitro and in vivo antibacterial activities of BO-2727, a new carbapenem. Antimicrob Agents Chemother (1995) 0.84
Identification of elongation factor G as the conserved cellular target of argyrin B. PLoS One (2012) 0.83
MexY-promoted aminoglycoside resistance in Pseudomonas aeruginosa: involvement of a putative proximal binding pocket in aminoglycoside recognition. MBio (2014) 0.81
Salt-inducible multidrug efflux pump protein in the moderately halophilic bacterium Chromohalobacter sp. Appl Environ Microbiol (2004) 0.81
AmgRS-mediated envelope stress-inducible expression of the mexXY multidrug efflux operon of Pseudomonas aeruginosa. Microbiologyopen (2014) 0.78
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 0.78
Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli. Eur J Clin Microbiol Infect Dis (2005) 0.77
Pentachlorophenol induction of the Pseudomonas aeruginosa mexAB-oprM efflux operon: involvement of repressors NalC and MexR and the antirepressor ArmR. PLoS One (2012) 0.77
NOVEL ANTIBIOTIC RESISTANCE DETERMINANTS FROM AGRICULTURAL SOIL EXPOSED TO ANTIBIOTICS WIDELY USED IN HUMAN MEDICINE AND ANIMAL FARMING. Appl Environ Microbiol (2017) 0.76
CpxR Activates MexAB-OprM Efflux Pump Expression and Enhances Antibiotic Resistance in Both Laboratory and Clinical nalB-Type Isolates of Pseudomonas aeruginosa. PLoS Pathog (2016) 0.75
Determinants of antibacterial spectrum and resistance potential of the elongation factor G inhibitor argyrin B in key Gram negative pathogens. Antimicrob Agents Chemother (2017) 0.75
Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System. Antimicrob Agents Chemother (2016) 0.75
Comparative in vitro activity of ciprofloxacin vs 8 antimicrobial agents against nosocomial multiresistant P. aeruginosa strains. Drugs (1995) 0.75
Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob Agents Chemother (1982) 5.67
Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant. Antimicrob Agents Chemother (1982) 4.98
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96
Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol (1980) 4.93
Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis (1986) 4.92
The genetic organization of arginine biosynthesis in Pseudomonas aeruginosa. Mol Gen Genet (1977) 4.07
Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes. J Bacteriol (1982) 3.94
Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 3.74
New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother (1990) 3.71
Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother (1987) 3.56
Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother (1988) 3.13
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. J Biol Chem (1990) 2.60
In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother (1989) 2.34
Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrob Agents Chemother (1989) 2.05
Increase in susceptibility of Pseudomonas aeruginosa to carbapenem antibiotics in low-amino-acid media. Antimicrob Agents Chemother (1991) 1.61
Diffusion of beta-lactam antibiotics through liposome membranes reconstituted from purified porins of the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 1.40
Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin. Antimicrob Agents Chemother (1990) 1.36
Decreases of the susceptibility to low molecular weight beta-lactam antibiotics in imipenem-resistant Pseudomonas aeruginosa mutants: role of outer membrane protein D2 in their diffusion. J Antimicrob Chemother (1990) 1.35
An esterase on the outer membrane of Pseudomonas aeruginosa for the hydrolysis of long chain acyl esters. J Biochem (1979) 1.23
Increased resistance to multiple drugs by introduction of the Enterobacter cloacae romA gene into OmpF porin-deficient mutants of Escherichia coli K-12. Antimicrob Agents Chemother (1991) 1.01
Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 3.98
Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 3.78
Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 2.67
Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1996) 2.18
K+ currents regulate the resting membrane potential, proliferation, and contractile responses in ventricular fibroblasts and myofibroblasts. Am J Physiol Heart Circ Physiol (2005) 1.89
Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol (2007) 1.75
Increase in susceptibility of Pseudomonas aeruginosa to carbapenem antibiotics in low-amino-acid media. Antimicrob Agents Chemother (1991) 1.61
Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 1.46
Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother (1995) 1.44
Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1996) 1.42
New cephamycin antibiotic, CS-1170: binding affinity to penicillin-binding proteins and inhibition of peptidoglycan cross-linking reactions in Escherichia coli. Antimicrob Agents Chemother (1978) 1.37
Local Ca(2+) transients and distribution of BK channels and ryanodine receptors in smooth muscle cells of guinea-pig vas deferens and urinary bladder. J Physiol (2001) 1.35
Penicillin-binding proteins in Proteus species. J Bacteriol (1979) 1.26
Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1986) 1.18
Isolation and structure of dynorphin, an opioid peptide, from porcine duodenum. Nature (1982) 1.16
Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother (1993) 1.13
C-type natriuretic peptide activates a non-selective cation current in acutely isolated rat cardiac fibroblasts via natriuretic peptide C receptor-mediated signalling. J Physiol (2007) 1.03
Loss of functional K+ channels encoded by ether-à-go-go-related genes in mouse myometrium prior to labour onset. J Physiol (2009) 1.01
Nature of magnetic coupling between Mn ions in As-grown Ga1-xMnxAs studied by X-ray magnetic circular dichroism. Phys Rev Lett (2008) 0.97
In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem. Antimicrob Agents Chemother (1997) 0.96
Hypersusceptibility of the Pseudomonas aeruginosa nfxB mutant to beta-lactams due to reduced expression of the ampC beta-lactamase. Antimicrob Agents Chemother (2001) 0.92
Ca2+ spark as a regulator of ion channel activity. Jpn J Pharmacol (1999) 0.91
Purification and some properties of beta-lactamases from Proteus rettgeri and Proteus inconstans. Microbiol Immunol (1980) 0.91
Apamin-sensitive Ca2+-dependent K+ current and hyperpolarization in human endothelial cells. Biochem Biophys Res Commun (1997) 0.90
Persistent production of interferon-gamma (IFN-gamma) and IL-12 is essential for the generation of protective immunity against Listeria monocytogenes. Clin Exp Immunol (1997) 0.90
Usefulness and limitation of DiBAC4(3), a voltage-sensitive fluorescent dye, for the measurement of membrane potentials regulated by recombinant large conductance Ca2+-activated K+ channels in HEK293 cells. Jpn J Pharmacol (2001) 0.90
Administration of killed bacteria together with listeriolysin O induces protective immunity against Listeria monocytogenes in mice. Immunology (1998) 0.90
Release of lipoteichoic acid from Staphylococcus aureus by treatment with cefmetazole and other beta-lactam antibiotics. J Antibiot (Tokyo) (1983) 0.89
Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol (1998) 0.89
Involvement of various combinations of endogenous inflammatory cytokines in Listeria monocytogenes-induced expression of inducible nitric oxide synthase in mice. FEMS Immunol Med Microbiol (1996) 0.87
Role of beta-lactamase of methicillin-susceptible Staphylococcus aureus in resistance to first-generation oral cephems both in vitro and in vivo. J Antimicrob Chemother (1994) 0.86
Penem derivatives: beta-lactamase stability and affinity for penicillin-binding proteins in Escherichia coli. Antimicrob Agents Chemother (1982) 0.84
Contribution of Kv2.1 channels to the delayed rectifier current in freshly dispersed smooth muscle cells from rabbit urethra. Am J Physiol Cell Physiol (2011) 0.84
Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice. Antimicrob Agents Chemother (1998) 0.84
Effect of 7 alpha substitution of cephems on their beta-lactamase stability and affinity for penicillin-binding proteins in Morganella morganii. Antimicrob Agents Chemother (1983) 0.83
Ca2+ sensitization of smooth muscle contractility induced by ruthenium red. Am J Physiol (1999) 0.79
Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC). Clin Exp Immunol (1998) 0.79
beta-Lactamase produced by a highly beta-lactam-resistant strain of Bacteroides fragilis: an obstacle to the chemotherapy of experimental mixed infections. J Antimicrob Chemother (1991) 0.78
Pharmacological and molecular evidence for the involvement of Kv4.3 in ultra-fast activating K+ currents in murine portal vein myocytes. Br J Pharmacol (2006) 0.78
Purification and properties of beta-lactamase from Proteus vulgaris. Microbiol Immunol (1982) 0.78
[Remission induction after pentoxifylline treatment in a patient with rheumatoid arthritis]. Ryumachi (1997) 0.78
Inhibitory activity to protein prenylation and antifungal activity of zaragozic acid D3, a potent inhibitor of squalene synthase produced by the fungus, Mollisia sp. SANK 10294. J Antibiot (Tokyo) (1998) 0.77
[Inhibition of biofilm formation by clarithromycin (CAM) in an experimental model of complicated bladder infection--in vitro study using automated simulation of urinary antimicrobial concentration]. Kansenshogaku Zasshi (1994) 0.76
Synthesis and antibacterial activity of novel 1beta-methyl carbapenems with cycloalkylamine moiety at the C-2 position. J Antibiot (Tokyo) (2001) 0.76
Hypothalamic ATF3 is involved in regulating glucose and energy metabolism in mice. Diabetologia (2013) 0.76
Potent cephalosporinase inhibitors: 7 beta-[2-(1, 3-dithiolan-2-ylidene) acetamido] cephalosporins and related compounds. Antimicrob Agents Chemother (1982) 0.75
[Application of serum type III procollagen peptide level in the diagnosis of lung fibrosis developed during bleomycin treatment in cancer patients]. Nihon Gan Chiryo Gakkai Shi (1985) 0.75
[Combination effect of teicoplanin and panipenem on highly resistant strains of MRSA]. Jpn J Antibiot (1999) 0.75
Molecular analysis of non-specific supersensitivity induced by AF64A in rat iris smooth muscle. J Smooth Muscle Res (2000) 0.75
Synthesis and biological evaluation of new oral carbapenems with 1-methyl-5-oxopyrrolidin-3-ylthio moiety. J Antibiot (Tokyo) (1999) 0.75
[In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae]. Jpn J Antibiot (1999) 0.75
[Combination effect between panipenem and vancomycin on highly methicillin-resistant Staphylococcus aureus]. Jpn J Antibiot (1997) 0.75
Synthesis and antifungal activities of R-102557 and related dioxane-triazole derivatives. Chem Pharm Bull (Tokyo) (2000) 0.75
[A quantitative study on phospholipids existing in periodontal pocket exudate with special reference to phosphatidylcholin, phosphatidylethanolamine and sphingomyelin values (author's transl)]. Nihon Shishubyo Gakkai Kaishi (1981) 0.75
[Significance of the combined treatment with isepamicin and piperacillin in an in vitro model for complicated cystitis operated by automatic simulator apparatus for urinary concentration]. Kansenshogaku Zasshi (1992) 0.75
[A clinical study on postantibiotic effect (PAE) and its application to chemotherapy for complicated cystitis with an automatic simulator of urinary drug concentration]. Kansenshogaku Zasshi (1992) 0.75
Effects of AF64A on the mRNA levels of muscarinic receptor subtypes in the rat iris sphincter. J Smooth Muscle Res (2000) 0.75
[Therapeutic study on biofilm of the urinary tract using a severely complicated bladder model (biofilm model of the urinary tract)--experimental study using an automatic simulator of urinary antimicrobial agent concentration, and clinical study]. Kansenshogaku Zasshi (1994) 0.75
Molecular cloning of m3 muscarinic acetylcholine receptor in rat iris. J Smooth Muscle Res (1998) 0.75
A novel phospholipase C inhibitor, S-PLI produced by Streptomyces sp. strain no. A-6288. J Enzyme Inhib (1996) 0.75
[Adaptation study for biofilm of the urinary tract via highly complicated bladder model (biofilm model of the urinary tract)--experimental study using automatic simulator of the urinary antimicrobial agent concentration]. Kansenshogaku Zasshi (1994) 0.75
[Study on MIC breakpoint and method of antimicrobial chemotherapy for moderately complicated urinary tract infection--study using an automatic simulator of urinary antimicrobial agent concentrations]. Kansenshogaku Zasshi (1994) 0.75
[An in vitro study on the treatment of complicated cystitis using an automatic simulator]. Kansenshogaku Zasshi (1990) 0.75
An assay method for secretin in crude preparations containing pancreozymin. Chem Pharm Bull (Tokyo) (1980) 0.75
Synthesis and biological evaluation of novel tricyclic carbapenems (trinems). J Antibiot (Tokyo) (2000) 0.75
Synthesis and in vitro antifungal activities of novel triazole antifungal agent CS-758. Chem Pharm Bull (Tokyo) (2001) 0.75
[In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae]. Jpn J Antibiot (2001) 0.75